Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LITT Combined With Pembrolizumab for Recurrent GBM
NCT03277638Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Nov 2017
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in glioblastoma (GBM), sponsored by Case Comprehensive Cancer Center. Started Nov 2017; status: completed.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03277638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03277638.